A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)
- 23 November 2015
- journal article
- clinical trial
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 140 (2), 245-252
- https://doi.org/10.1016/j.ygyno.2015.11.026
Abstract
No abstract availableKeywords
Funding Information
- Johns Hopkins/UAB Cervical Cancer (SPORE NCI 1 P50 CA098252)
- NCI NExT Program (#471)
This publication has 31 references indexed in Scilit:
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage LevelsJNCI Journal of the National Cancer Institute, 2013
- Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccinationJournal of Biomedical Science, 2010
- Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasiaBritish Journal of Cancer, 2010
- Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3Cancer Immunology, Immunotherapy, 2009
- Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical DevelopmentsMolecular Therapy, 2009
- A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3Clinical Cancer Research, 2008
- Type-Dependent Integration Frequency of Human Papillomavirus Genomes in Cervical LesionsCancer Research, 2008
- Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcriptsOncogene, 2007
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- ZYC101a for Treatment of High-Grade Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2004